The first two domestically produced generic drugs are about to go on the market!

　　Pharmaceutical network November 22nd, the world's heavyweight varieties of Bevala zhu mono-resistance, domestic first imitation will soon be listed; 　　On November 21, inight database showed that Jiangsu Hengrui 3 generic drug? Aceketone hydrochloric acid injection? The status of the domestic listing application changed to ?approved - to be certified?—— after a round of supplementary information and clinical trial site verification, is expected to be approved for listing soon public information shows that the acetaminophen hydrochloric acid injection is an analgesic and increased dose-induced anaesthetic derivative of the hand cyclone, mainly by blocking N-methyl-D-winterinic intake (NMDA) receptors to play analgesic effect In 2017, global sales of ACEketone hydrochloride injections were approximately $12 million at present, only Hengrui a declared on the market, Johnson and Johnson's hydrochloric acid esbutramine nasal spray is being declared clinical, located in the special review channel in other words, Hengrui's acetaminophen hydrochloride injection has overtaken the original research in the declaration process and may be the first to be listed in the future at the same time, Qilu Pharmaceutical's Bevalu mono-anti-biosimilar drug? Review status changed to ?in the review? After two rounds of supplementary information and clinical production site verification, the first domestic bevalasingle anti-biosimilar drug may be listed bebazumab is an anti-
angiogenesis inhibitor, can block the growth of new blood vessels of tumor, and tumor cell growth and metastasis and the production of new blood vessels is very much related, the new blood vessel is the way of tumor nutrition supply, bavarmono can block the binding between receptors to inhibit tumor angiogenesis Bevan Pearl Santi (the name: Anvetin) is one of Roche's "three carriages" and has made an important contribution to Roche's rapid growth The total sales of the injection with qutoberimono resistance, the litoxia monoantigen and the beval bead monoantigen in 2018 exceeded 9.7 billion yuan, and Roche occupied 80% of the market for anti-tumor monoantigen at the end of China's public medical institutions and this Qilu's first domestic beevarpearl resistance is about to be approved, or will be a major situation for Roche the first imitation of the domestic, bringing the original research drug "patent cliff" has been an industry expert to Seiber Blue said that if the product wants to enter the health insurance, the existence of the first imitation will make the government cut the price of more, the patent cliff effect is more obvious to the tumor drug Giifitini as an example, the original research drug to 5000 yuan / box price domestic listing, AstraZeneca in Qilu's domestic Giifitini on the eve of the listing, through state negotiations, the price from 5000 yuan to 2358 yuan, a decline of more than 50% in addition, in order to hit the beat of Thedruge Pharmaceuticals' Ektini, Roche's Elotini and Ziru's Giofinib, a sharp reduction of 76% in a price-for-price, into the 4 plus 7 national band Tian Ling, deputy general manager of the research and development center of Jinzhou Aohong Pharmaceutical Research and Development Center in
jinzhou, , told Saiper Blue that generic drugs can affect the original drug in many ways On the one hand is the price, generic drugs will be forced to reduce the price of the original drug after the market, on the other hand is the market, especially orphan drugs, because in the case of relatively limited patients, generic drugs will certainly divide the original research drug patients, resulting in a decline in the market share of the original research it is understood that in the past, the price of 100mg: 4ml of Aveitin is 5398 yuan, its price on July 19, 2017 after entering health insurance fell to 1998 yuan (100mg: 4ml/bottle) the recommended dose of bevazumab is 5 mg/kg, every 14 days to give medicine, to weight of 60 kg of patients, the need to use 300 mg metering medicine, calculated as 3 bottles, the price of 5994 yuan; The proportion of patients' out-of-pocket expenses will vary from patient to patient note that because the 2017 Bevalbeu-dupreenter son-in-line is in the health insurance list, the agreement period needs to be renegotiated by 2019, and it is on the list of varieties to be renewed This time in the domestic first imitation drug on the eve of the negotiations, perhaps beva pearl single resistance will usher in a new round of price cuts 　　To some extent, strip sourcing has completely changed the logic of the generics industry, moving from sales-driven to cost-driven, where generics, hard-to-counterfeit, improved new drugs and generics that can make technological breakthroughs will become the darlings of the market because the first imitation has a certain competitive advantage, so in recent years many enterprises are working hard to lay out the first imitation Tian Ling told Cypress Blue: It is difficult for companies to control their first copy 100 percent - even if your product is the first to declare, but due to the uncertainty of the approval process, it is not always the first batch, unless competitors lag far behind home-declared products in addition, for enterprises, even if the first imitation of the market, if the product does not enter the health insurance, non-base drugs, coupled with the recent the frequency of drug sessions is relatively low and other reasons, sales are very difficult, it is difficult to have rapid growth to this, the above-mentioned professionals put forward: for many domestic enterprises, the generic or to do generic drugs, on the one hand, innovative drug research and development costs are high, and the clinical risk in the research and development process is also very high, failure may be all the profits of the enterprise consumption, so the enterprise to do the same, the generic drug is still to be done But in the direction of generic drugs, there can be some corresponding adjustments: a trend: the enterprise's production capacity is very large, not afraid of price reduction, but the sales terminal is not good, can do now or in the future may enter the national collection of varieties, with collection to consume capacity another situation: small capacity, high cost of enterprises, in the transformation can choose some technically difficult products, or slow-control release, in this process, the enterprise while imitation, while making their own strategic adjustment, while the adjustment process of dynamic abandonment Qilu, Zhengda Tianqing, etc is the first imitation of the king, mainly because a few years ago, the first imitation of the varieties, no matter how the policy changes, they always do not give up, and finally bear fruitful fruit
"Enterprises should be based on their own circumstances, to determine the strategic direction of development, many years of research and development to persist in efforts, will eventually have a harvest." Tian Ling told Seiber Blue.